Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 64,381 | 57,424 | 51,346 | 55,311 | 71,857 |
| Gross Profit | 64,381 | 57,424 | 51,346 | 55,311 | 71,857 |
| Operating Expenses | 111,330 | 113,459 | 143,303 | 313,095 | 369,484 |
| Operating Income | -46,949 | -56,035 | -91,957 | -257,784 | -297,627 |
| Interest Expense | 2,546 | 2,350 | 6,369 | 8,547 | 8,547 |
| Other Income | 4,881 | 9,116 | 5,511 | 1,109 | 2,831 |
| Pre-tax Income | -44,614 | -49,269 | -92,815 | -265,222 | -303,343 |
| Income Tax | 11,804 | 5,924 | 9 | -151 | -8,520 |
| Net Income Continuous | -56,418 | -55,193 | -92,824 | -265,071 | -294,823 |
| Net Income Discontinuous | N/A | N/A | 964,956 | 65,645 | 16,806 |
| Net Income | $-56,418 | $-55,193 | $872,132 | $-199,426 | $-278,017 |
| EPS Basic Total Ops | -1.15 | -1.00 | 11.85 | -2.87 | -4.46 |
| EPS Basic Continuous Ops | -1.16 | -1.00 | -1.26 | -3.82 | -4.73 |
| EPS Basic Discontinuous Ops | N/A | N/A | 13.11 | 0.95 | 0.27 |
| EPS Diluted Total Ops | -1.15 | -1.00 | 11.85 | -2.87 | -4.46 |
| EPS Diluted Continuous Ops | -1.16 | -1.00 | -1.26 | -3.82 | -4.73 |
| EPS Diluted Discontinuous Ops | N/A | N/A | 13.11 | 0.95 | 0.27 |
| EPS Diluted Before Non-Recurring Items | -1.15 | -1.00 | -1.26 | -2.87 | -4.20 |
| EBITDA(a) | $-47,748 | $-55,931 | $-88,922 | $-252,972 | $-293,999 |